Synergistic antitumor effects of liposomal honokiol combined with cisplatin in colon cancer models

Oncology Letters

Volumn 2, Issue 5, 2011, Pages 957-962

  Cheng, Niang ^a   Xia, Tian ^a   Han, Ying ^a   He, Qing Jun ^a   Zhao, Rong ^a   Ma, Jun Rong ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Antiangiogenesis; Apoptosis; Cisplatin; Honokiol; Liposome

Indexed keywords

CISPLATIN; HONOKIOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL DENSITY; COLON CANCER; CONTROLLED STUDY; DRUG POTENTIATION; ENDOTHELIUM CELL; FEMALE; FLOW CYTOMETRY; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NICK END LABELING; NONHUMAN;

EID: 79960317593     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.350     Document Type: Article

References (31)

1. Arriagada R, Bergman B, Dunant A, et al: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350: 351-360, 2004.
2. Olaussen KA, Dunant A, Fouret P, et al: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355: 983-991, 2006.
3. Perez RP: Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 34: 1535-1542, 1998.
4. Rossi A, Maione P and Gridelli C: Safety profile of platinum-based chemotherapy in the treatment of advanced non-small cell lung cancer in elderly patients. Expert Opin Drug Saf 4: 1051-1067, 2005.
5. Perrotta C, Bizzozero L, Falcone S, et al: Nitric oxide boosts chemoimmunotherapy via inhibition of acid sphingomyelinase in a mouse model of melanoma. Cancer Res 67: 7559-7564, 2007.
6. Bai X, Cerimele F, Ushio-Fukai M, et al: Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J Biol Chem 278: 35501-35507, 2003.
7. Hibasami H, Achiwa Y, Katsuzaki H, et al: Honokiol induces apoptosis in human lymphoid leukemia Molt 4B cells. Int J Mol Med 2: 671-673, 1998.
8. Wang T, Chen F, Chen Z, et al: Honokiol induces apoptosis through p53-independent pathway in human colorectal cell line RKO. World J Gastroenterol 10: 2205-2208, 2004.
9. Yang SE, Hsieh MT, Tsai TH and Hsu SL: Down-modulation of Bcl-XL, release of cytochrome c and sequential activation of caspases during honokiol-induced apoptosis in human squamous lung cancer CH27 cells. Biochem Pharmacol 63: 1641-1651, 2002.
10. Reimer CL, Agata N, Tammam JG, et al: Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, an inhibitor of angiogenesis. Cancer Res 62: 789-795, 2002.
11. Konoshima T, Kozuka M, Tokuda H, et al: Studies on inhibitors of skin tumor promotion, IX. Neolignans from Magnolia officinalis. J Nat Prod 54: 816-822, 1991.
12. Jin ZJ: Addition in drug combination. Acta Pharmacol Sin 1: 70-76, 1980.
13. Malaguarnera L: Implications of apoptosis regulators in tumorigenesis. Cancer Metastasis Rev 23: 367-387, 2004.
14. Ferreira CG, Epping M, Kruyt FA and Giaccone G: Apoptosis: target of cancer therapy. Clin Cancer Res 8: 2024-2034, 2002.
15. Zupi G, Scarsella M, Semple SC, Mottolese M, Natali PG and Leonetti C: Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence. Clin Cancer Res 11: 1990-1998, 2005.
16. Bourhis J, Rivera F, Mesia R, et al: Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 24: 2866-2872, 2006.
17. Van Antwerp DJ, Martin SJ, Kafri T, Green DR and Verma IM: Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 274: 787-789, 1996.
18. Hsu H, Shu HB, Pan MG and Goeddel DV: TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 84: 299-308, 1996.
19. Deng Y, Ren X, Yang L, Lin Y and Wu X: A JNK-dependent pathway is required for TNFalpha-induced apoptosis. Cell 115: 61-70, 2003.
20. Weitsman GE, Ravid A, Liberman UA and Koren R: Vitamin D enhances caspase-dependent and -independent TNFalpha-induced breast cancer cell death: the role of reactive oxygen species and mitochondria. Int J Cancer 106: 178-186, 2003.
21. Lüschen S, Scherer G, Ussat S, Ungefroren H and Adam-Klages S: Inhibition of p38 mitogen-activated protein kinase reduces TNF-induced activation of NF-kappaB, elicits caspase activity, and enhances cytotoxicity. Exp Cell Res 293: 196-206, 2004.
22. Nio Y, Zighelboim J, Berek J and Bonavida B: Cycloheximide-induced modulation of TNF-mediated cytotoxicity in sensitive and resistant ovarian tumor cells. Cancer Chemother Pharmacol 26: 1-8, 1990.
23. Sasaki H, Sheng Y, Kotsuji F and Tsang BK: Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res 60: 5659-5666, 2000.
24. Yoshikawa A, Saura R, Matsubara T and Mizuno K: A mechanism of cisplatin action: antineoplastic effect through inhibition of neovascularization. Kobe J Med Sci 43: 109-120, 1997.
25. Ahn KS, Sethi G, Shishodia S, Sung B, Arbiser JL and Aggarwal BB: Honokiol potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through modulation of nuclear factor-kappaB activation pathway. Mol Cancer Res 4: 621-633, 2006.
26. Senior JH: Fate and behavior of liposomes in vivo: a review of controlling factors. Crit Rev Ther Drug Carrier Syst 3: 123-193, 1987.
27. Ranade VV: Drug delivery systems. 1. site-specific drug delivery using liposomes as carriers. J Clin Pharmacol 29: 685-694, 1989.
28. Rahman YE, Hanson WR, Bharucha J, Ainsworth EJ and Jaroslow BN: Mechanisms of reduction of antitumor drug toxicity of liposome encapsulation. Ann N Y Acad Sci 308: 325-341, 1978.
29. Webb MS, Harasym TO, Masin D, Bally MB and Mayer LD: Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincri-stine in murine and human tumour models. Br J Cancer 72: 896-904, 1995.
30. Yuan F, Dellian M, Fukumura D, et al: Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 55: 3752-3756, 1995.
31. Gabizon AA: Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 19: 424-436, 2001